NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

BMRA | NASDAQ

$2.26 -$0.04 | -1.74%
SIGNAL:Signal available — unlock to view |2026-09-25 |F&G 76 |RSI 50.6

Company Overview:

Market Cap: $6.94M
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $1.45 - $3.21

10 Year BMRA Performance Metrics:

Total Return (with DRIP): -90.2% (-20.72% CAGR)
Total Return (no DRIP): -90.2% (-20.72% CAGR)
Share Price: -89.2% (-19.94% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $981
Total Return $ (with DRIP): -$9,019
BMRA Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
BMRA Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

BMRA Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

BMRA - Revenue
BMRA Revenue CAGR:1Y: -11.80%2Y: -1.49%5Y: -22.92%10Y: -3.17%
BMRA - Earnings Per Share (EPS)
BMRA EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Net Income
🔓 See the full chart40% off right now · 7-day free trial
BMRA Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - EBITDA
🔓 See the full chart40% off right now · 7-day free trial
BMRA EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Free Cash Flow
🔓 See the full chart40% off right now · 7-day free trial
BMRA Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Free Cash Flow / Share
🔓 See the full chart40% off right now · 7-day free trial
BMRA Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Operating Income
🔓 See the full chart40% off right now · 7-day free trial
BMRA Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Gross Profit
🔓 See the full chart40% off right now · 7-day free trial
BMRA Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Shares Outstanding
🔓 See the full chart40% off right now · 7-day free trial
BMRA Shares Outstanding CAGR:1Y: -82.42%2Y: -57.70%5Y: -24.04%10Y: -8.87%
BMRA - Share Buybacks
🔓 See the full chart40% off right now · 7-day free trial
BMRA Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Stock-Based Comp
🔓 See the full chart40% off right now · 7-day free trial
BMRA Stock-Based Comp CAGR:1Y: 12.50%2Y: -37.08%5Y: -10.64%10Y: 19.20%
BMRA - Expenses
🔓 See the full chart40% off right now · 7-day free trial
BMRA Expenses CAGR:1Y: 375.00%2Y: 8.97%5Y: -28.34%10Y: -7.56%
BMRA - Revenue vs Net Income
🔓 See the full chart40% off right now · 7-day free trial
BMRA - EPS vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
BMRA - EPS vs PE Ratio
🔓 See the full chart40% off right now · 7-day free trial
BMRA - FCF vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
BMRA - FCF vs Stock Based Comp
🔓 See the full chart40% off right now · 7-day free trial
BMRA - Cash & Debt
🔓 See the full chart40% off right now · 7-day free trial
BMRA - Revenue by Segment
🔓 See the full chart40% off right now · 7-day free trial
BMRA Revenue CAGR:1Y: -11.80%2Y: -1.49%5Y: -22.92%10Y: -3.17%
BMRA - Revenue by Region
🔓 See the full chart40% off right now · 7-day free trial
BMRA Revenue CAGR:1Y: -11.80%2Y: -1.49%5Y: -22.92%10Y: -3.17%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

BMRA - REVENUE: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
BMRA Actual Revenue CAGR:1Y: -11.80%2Y: -1.49%5Y: -22.92%10Y: -3.17%
BMRA - EPS: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
BMRA Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - NET INCOME: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
BMRA Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - EBITDA: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
BMRA Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

BMRA - Net Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
BMRA Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Gross Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
BMRA Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Price to Earnings
🔓 See the full chart40% off right now · 7-day free trial
BMRA Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Price To Sales Ratio
🔓 See the full chart40% off right now · 7-day free trial
BMRA Price To Sales Ratio CAGR:1Y: -92.95%2Y: -80.18%5Y: -47.80%10Y: -18.55%
BMRA - Return on Capital Employed
🔓 See the full chart40% off right now · 7-day free trial
BMRA Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BMRA - Return on Invested Capital
🔓 See the full chart40% off right now · 7-day free trial
BMRA Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for BMRA

Based on past 10-year performance, here are BMRA growth metrics:

Share price CAGR of -19.94%
Dividend CAGR of +0%

Using BMRA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

BMRA (DRIP)BMRA - No DRIP
Current Price$2.26$2.26
Start Shares4,424.784,424.78
Start Value$10,000$10,000
  
After 10 years:
Final Share Count4,424.784,424.78
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$0.24$2.26
Total Dividends$0$0
Final Value$1,082$10,000

Estimated Future Value + Dividends - BMRA

NOTE: Above numbers are our estimate based on BMRA's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

Biomerica, Inc. (BMRA) had its IPO on 1984-09-07, and is traded on NASDAQ stock exchange.

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

BMRA website: https://www.biomerica.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — BMRA

Value from:
Pay up to today
—
vs current price $2.26
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →